TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06692153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: An AID System.
Description: The embecta Automated Insulin Delivery (AID) System is a closed loop system comprised of 3 components: the embecta insulin pump, a Smartphone with the Tidepool Loop app, and the Dexcom G6 CGM

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: An AID System.
Description: The embecta Automated Insulin Delivery (AID) System is a closed loop system comprised of 3 components: the embecta insulin pump, a Smartphone with the Tidepool Loop app, and the Dexcom G6 CGM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SC)
Description: Participants will continue to use their current therapy for T2D.
Study: NCT06700356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phase 1-Validation of thalamus seizure detection with concurrent video EEG monitoring
Description: Epilepsy monitoring unit evaluation will follow standard of care practices for seizure characterization, and antiseizure medications may be reduced to facilitate the recording of seizures. Patient clinical management, and video-EEG interpretation will be completed by the clinical epilepsy monitoring unit team which consists of physicians, nurse practitioners, registered nurses, and in-house 24-hour 7-days-per-week EEG technicians. Continuous full-bandwidth thalamus recordings (250 Hz) will be acquired by the research study team using a standard clinician programmer and telemetry module. Hospital monitoring will last up to 4 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phase 2-DBS Stimulation with Medtronic Percept DBS device-Out Patient
Description: Patients will then transition to the ambulatory phase. In the outpatient setting, patients will have constrained ambulatory thalamus recordings using recording parameters determined by Phase 1. DBS treatment stimulation will be programmed in the clinical epilepsy neuromodulation lab using typical high frequency (\>50 Hz) stimulation. High frequency stimulation is the conventional approach to DBS for epilepsy, as was used in the pivotal study leading to premarket approval (SANTE study)2 of anterior nucleus of the thalamus (ANT) DBS for focal epilepsy, which is typical for epilepsy DBS practice3, and several studies of DBS for generalized epilepsy4-6, in a sensing friendly electrode configuration. Patients will keep a detailed seizure diary. Ambulatory thalamus recordings by the DBS system and patient reported seizure diaries will be collected during routine clinical DBS programming visits (q3-9 months).
Study: NCT06704932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR446959
Description: Pharmaceutical form:solution for injection-Route of administration:Intra-articular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:solution for injection-Route of administration:Intra-articular injection
Study: NCT06726174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECCEC
Description: 0.5-1x10\^6 cells/300 uL, intracameral injection.
Study: NCT06735235

Intervention type: DRUG
Group type: OTHER
Intervention: 0 ppm F
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

Intervention type: DRUG
Group type: OTHER
Intervention: 0 ppm F
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

Intervention type: DRUG
Group type: OTHER
Intervention: 0 ppm F
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

Intervention type: DRUG
Group type: OTHER
Intervention: 0 ppm F
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

Intervention type: DRUG
Group type: OTHER
Intervention: 250 ppm F as MFP
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

Intervention type: DRUG
Group type: OTHER
Intervention: 250 ppm F as MFP
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

Intervention type: DRUG
Group type: OTHER
Intervention: 250 ppm F as MFP
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

Intervention type: DRUG
Group type: OTHER
Intervention: 250 ppm F as MFP
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

Intervention type: DRUG
Group type: OTHER
Intervention: 1100 ppm as MFP
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

Intervention type: DRUG
Group type: OTHER
Intervention: 1100 ppm as MFP
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

Intervention type: DRUG
Group type: OTHER
Intervention: 1100 ppm as MFP
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

Intervention type: DRUG
Group type: OTHER
Intervention: 1100 ppm as MFP
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

Intervention type: DRUG
Group type: OTHER
Intervention: 2800 ppm F as MFP
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

Intervention type: DRUG
Group type: OTHER
Intervention: 2800 ppm F as MFP
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

Intervention type: DRUG
Group type: OTHER
Intervention: 2800 ppm F as MFP
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

Intervention type: DRUG
Group type: OTHER
Intervention: 2800 ppm F as MFP
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Study: NCT06736158

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic testing for inherited bleeding disorders
Description: Gene panel for bleeding: This analysis will look at a list of genes known to be associated with rare coagulation, platelet, connective tissue, and bleeding disorders. There are currently 318 genes on the panel however this list may be updated throughout the study. Genes of study include those on the the International Society of Thrombosis and Haemostasis (ISTH) TIER-1 and TIER-2 gene list, as well as additional genes identified in published research.
Study: NCT06734013

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Molecular diagnostic
Description: RNA will be analysed using a Real-Time PCR expression card (TaqMan Real-Time PCR assay technology - Thermo Fisher Scientific). The analysis will be performed using a Real-Time Light Cycler 480 (Roche). The expression card will be customised for the study, including the genes cxcl9/10, cav-1, rhoj, cdh5, cd96, tnfsf8, il-21r, vcam, klrk1
Study: NCT06735170

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biologic tuberoplasty
Description: a surgical procedure during which an a cellular dermal allograft is attached to the greater tuberosity to prevent bone-to-bone contact between the greater tuberosity and the acromion with the goal of decreasing pain

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subacromial balloon spacer
Description: a biodegradable balloon is inserted into the subacromial space of the shoulder to increase teh distance between the greater tuberosity and the acromion to reduce pain
Study: NCT06736431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-based resource referral platform with diabetes educational materials
Description: Text-based resource referral platform with diabetes educational materials
Study: NCT06735885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Matter Neuroscience App
Description: An iPhone smartphone application

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Matter Neuroscience App
Description: An iPhone smartphone application

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Matter Neuroscience App
Description: An iPhone smartphone application

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stock Photos
Description: Stock Photos

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stock Photos
Description: Stock Photos

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stock Photos
Description: Stock Photos

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Home Training
Description: No Home Training
Study: NCT06736171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Exoskeleton
Description: EksoNR, Ekso Bionics, San Rafael, CA, USA Atalante X, Wandercraft, Paris, France ReStore™, Lifeward Inc, Marlborough, MA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: Standard of Care
Study: NCT06736119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task Oriented Intervention
Description: Intervention group will recieve task oriented interventions.Throwing and catching balls of different sizes and weights will be done. For writing, a task-oriented approach has 4 phases that will involve writing,correcting and fun writing 30-minute per session. Interventions provided 3 days per week for 3 months.
Study: NCT06736288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BUCCALIN®
Description: Gastro-resistant tablets (mixture of Streptococcus pneumoniae I, II, III, Streptococcus agalactiae, Staphylococcus aureus, Haemophilus influenzae).~The recommended dosage is 1 tablet on day 1, 2 tablets on day 2, and 4 tablets on day 3 and should be taken in the morning on an empty stomach.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gastro-resistant tablets containing only excipients). The recommended dosage is 1 tablet on day 1, 2 tablets on day 2, and 4 tablets on day 3 and should be taken in the morning on an empty stomach.
Study: NCT06734936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Playing videos with sgg
Description: Playing videos with sgg
Study: NCT05433168

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SHIATSU
Description: The patients will benefit from shiatsu treatments by a professional according to the shiatsu protocol developed by the Syndicate's evaluation commission Shiatsu Professionals (SPS).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SHIATSU
Description: The patients will benefit from shiatsu treatments by a professional according to the shiatsu protocol developed by the Syndicate's evaluation commission Shiatsu Professionals (SPS).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DUMMY SHIATSU
Description: Exercising a fake shiatsu is a real problem as opinions differ. The consensus of the different schools and styles of the technique is that shiatsu pressure is weight transfer. We are therefore going to remove this aspect from the SFASPA shiatsu protocol. The professional will run the same sequence of points, without any weight transfer, being only in contact with the receiver

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DUMMY SHIATSU
Description: Exercising a fake shiatsu is a real problem as opinions differ. The consensus of the different schools and styles of the technique is that shiatsu pressure is weight transfer. We are therefore going to remove this aspect from the SFASPA shiatsu protocol. The professional will run the same sequence of points, without any weight transfer, being only in contact with the receiver
Study: NCT04651010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal MRI
Description: Multimodal MRI will be realized between 12 and 24 hours after thrombectomy
Study: NCT06318897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV
Study: NCT06352827

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Survey
Description: All participants will complete a baseline survey and have medical information collected.
Study: NCT05683171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valemetostat
Description: Given by PO
Study: NCT05548452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intestinal Microbiota Transplant (IMT) Capsules
Description: Capsules containing freeze-dried intestinal microbiota from healthy human donors

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: Capsules containing an inactive substance (sugar pill)
Study: NCT06291285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine-THU
Description: Orally administered immediate release tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine-THU
Description: Orally administered immediate release tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine-THU
Description: Orally administered delayed release capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine-THU
Description: Orally administered delayed release capsules.
Study: NCT05591274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmileyScope Virtual Reality Headset
Description: The SmileyScope Virtual Reality Headset is a VR headset undergoing study for approval by the U.S. Food and Drug Administration (FDA) to reduce pain and anxiety in patients aged 4 years and older undergoing needle blood draw or injection procedures. Currently, this device has been granted entrance to the FDA Safer Technologies Program. The device comes pre-loaded with either an interactive or static virtual reality scenario.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmileyScope Virtual Reality Headset
Description: The SmileyScope Virtual Reality Headset is a VR headset undergoing study for approval by the U.S. Food and Drug Administration (FDA) to reduce pain and anxiety in patients aged 4 years and older undergoing needle blood draw or injection procedures. Currently, this device has been granted entrance to the FDA Safer Technologies Program. The device comes pre-loaded with either an interactive or static virtual reality scenario.
Study: NCT05452850

Intervention type: DIAGNOSTIC_TEST
Intervention: Left and Right Ventricular Global Strain Imaging
Description: Two-dimensional, color Doppler, spectral Doppler, and 3D digital echocardiographic image recordings will be taken from parasternal, apical, subcostal, and modified sections using a Philips Epiq CVx echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed with speckle tracking echocardiography from these recordings.
Study: NCT05562895

Intervention type: DEVICE
Intervention: Ion Endoluminal System and Cios Spin
Description: Integrated version of the Ion Endoluminal System and Cios Spin
Study: NCT03986086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPH966
Description: RP2D tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MPH966 placebo table
Study: NCT05973617

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of corneal biomechanical properties
Description: Measurement of corneal biomechanics

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of corneal biomechanical properties
Description: Measurement of corneal biomechanics

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of corneal biomechanical properties
Description: Measurement of corneal biomechanics

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of corneal biomechanical properties
Description: Measurement of corneal biomechanics
Study: NCT04968197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular Intervention via Portable Electrical Stimulator (VIPES) system
Description: A small, lightweight device able to deliver stochastic vestibular stimulation (SVS) using a comfortable electrode set on the back of the head as well as other proven modes of galvanic vestibular stimulation (GVS) related vestibular correction when required to mitigate motion sickness or provide auxiliary vestibular cueing.
Study: NCT05137496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 0.3mg/kg/d, iv.gtt, for at least 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 2mg/kg, d1-d5, gradually reduced, for at least 2 weeks
Study: NCT05158933

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study: NCT06408649

Intervention type: DEVICE
Intervention: Lehfilcon A spherical contact lenses
Description: Silicone hydrogel contact lenses for the correction of ametropia (myopia or hyperopia)

Intervention type: DEVICE
Intervention: Lehfilcon A toric contact lenses
Description: Silicone hydrogel contact lenses for the correction of ametropia (myopia or hyperopia) with astigmatism
Study: NCT04703478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercise
Description: Participants will carry out a breathing exercise program through the RespiraConNosotros mobile application. They will be asked to carry out the proposed exercises with a frequency of 3 times a week for 3 months.
Study: NCT04946903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2007
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2007
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2008
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2008
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1902
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1902
Description: Take it once per period.
Study: NCT06570044

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PerioMonitor
Description: Collection of oral rinse specimen and perform the PerioMonitor test as per the method described in the instructions for use
Study: NCT04624880

Intervention type: DEVICE
Intervention: Giant magnetoresistive sensor (GMR)
Description: Giant magnetoresistive sensor analyzes genetic polymorphisms in patient samples.

Intervention type: DEVICE
Intervention: Giant magnetoresistive sensor (GMR)
Description: Giant magnetoresistive sensor analyzes genetic polymorphisms in patient samples.
Study: NCT05477381

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of cervical stiffness by Pregnolia Device
Description: The Pregnolia® System is designed to provide information about the mechanical properties of the cervical tissue by assessing the CSI (Cervical Stiffness Index) through a probe that will create a weak vacuum to retract tissue. The Pregnolia® System is designed with the purpose to provide an alternative diagnostic marker to identify women at risk of spontaneous PTB.~The Pregnolia® System is a CE-marked device developed for quantitative assessment of softening of the uterine cervix.~The Pregnolia® System will be applied within its intended use.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of cervical stiffness by Pregnolia Device
Description: The Pregnolia® System is designed to provide information about the mechanical properties of the cervical tissue by assessing the CSI (Cervical Stiffness Index) through a probe that will create a weak vacuum to retract tissue. The Pregnolia® System is designed with the purpose to provide an alternative diagnostic marker to identify women at risk of spontaneous PTB.~The Pregnolia® System is a CE-marked device developed for quantitative assessment of softening of the uterine cervix.~The Pregnolia® System will be applied within its intended use.
Study: NCT05612477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autotransfusion
Description: blood is collected from the surgical field, washed, processed and transfused back into the patient
Study: NCT04293406

Intervention type: OTHER
Intervention: Decision Navigation Intervention (DNI)
Description: This study will develop and test the acceptability and feasibility of a decision navigation intervention (DNI) for AA or H/L men with prostate cancer through consideration of the role of partners and family members in the decision-making process. In the decision navigation intervention (DNI), participants will meet with the navigator in person or via phone, prior to their specialist treatment consultation. At the end of the DNI visit, participants will receive a personalized list of prioritized questions. At the end of the decision navigation appointment, all navigated patients will complete a five-item navigation rating scale evaluating the intervention and its impact on their preparation for the consultation visit.
Study: NCT06233136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leg pedalling exercise
Description: Each child in the experimental group will be positioned in inclined position and will cycle through the range of motion under the supervision of the researcher

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The designed physical therapy program
Description: It applied for all participated children in both groups. It includes;~1. Flexibility exercises~2. Static and dynamic balance~3. Functional training exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The designed physical therapy program
Description: It applied for all participated children in both groups. It includes;~1. Flexibility exercises~2. Static and dynamic balance~3. Functional training exercises
Study: NCT01725516

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofascial release technique
Study: NCT00767988

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Urex-cap-5 (2x10^9 cfu each of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1)
Description: Capsules once daily at approximately the same time each day for 6 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule once daily at approximately the same time each day for 6 months.